Table 1.
Association between LIN28B gene polymorphisms and hepatoblastoma susceptibility
| Genotype | Cases (N=275) | Controls (N=1017) | P a | Crude OR (95% CI) | P | Adjusted OR (95% CI) b | P b |
|---|---|---|---|---|---|---|---|
| rs314276 (HWE=0.209) | |||||||
| CC | 123 (44.73) | 483 (47.49) | 1.00 | 1.00 | |||
| CA | 107 (38.91) | 448 (44.05) | 0.94 (0.70-1.25) | 0.664 | 0.94 (0.70-1.26) | 0.672 | |
| AA | 45 (16.36) | 86 (8.46) | 2.06 (1.36-3.10) | 0.0006 | 2.05 (1.36-3.10) | 0.0006 | |
| Additive | 0.017 | 1.27 (1.04-1.55) | 0.018 | 1.27 (1.04-1.55) | 0.018 | ||
| Dominant | 152 (55.27) | 534 (52.51) | 0.415 | 1.12 (0.86-1.46) | 0.415 | 1.12 (0.86-1.46) | 0.409 |
| Recessive | 230 (83.64) | 931 (91.54) | 0.0001 | 2.12 (1.44-3.12) | 0.0002 | 2.11 (1.43-3.12) | 0.0002 |
| rs221634 (HWE=0.969) | |||||||
| AA | 94 (34.55) | 342 (33.63) | 1.00 | 1.00 | |||
| AT | 144 (52.36) | 495 (48.67) | 1.05 (0.78-1.40) | 0.758 | 1.04 (0.78-1.40) | 0.772 | |
| TT | 36 (13.09) | 180 (17.70) | 0.72 (0.47-1.10) | 0.129 | 0.72 (0.47-1.10) | 0.130 | |
| Additive | 0.239 | 0.89 (0.73-1.08) | 0.239 | 0.89 (0.73-1.08) | 0.239 | ||
| Dominant | 180 (65.45) | 675 (66.37) | 0.776 | 0.96 (0.73-1.27) | 0.775 | 0.96 (0.72-1.27) | 0.765 |
| Recessive | 239 (86.91) | 837 (82.30) | 0.069 | 0.70 (0.48-1.03) | 0.071 | 0.70 (0.48-1.03) | 0.073 |
| rs221635 (HWE=0.139) | |||||||
| TT | 185 (67.27) | 652 (64.11) | 1.00 | 1.00 | |||
| TC | 79 (28.73) | 315 (30.97) | 0.88 (0.66-1.19) | 0.413 | 0.88 (0.66-1.19) | 0.407 | |
| CC | 11 (4.00) | 50 (4.92) | 0.78 (0.40-1.52) | 0.459 | 0.78 (0.40-1.52) | 0.458 | |
| Additive | 0.300 | 0.88 (0.70-1.12) | 0.300 | 0.88 (0.70-1.12) | 0.296 | ||
| Dominant | 90 (32.73) | 365 (35.89) | 0.330 | 0.87 (0.66-1.15) | 0.330 | 0.87 (0.65-1.15) | 0.325 |
| Recessive | 264 (96.00) | 967 (95.08) | 0.525 | 0.81 (0.41-1.57) | 0.526 | 0.81 (0.41-1.57) | 0.527 |
| rs9404590 (HWE=0.868) | |||||||
| TT | 141 (51.27) | 558 (54.87) | 1.00 | 1.00 | |||
| TG | 102 (37.09) | 392 (38.54) | 1.03 (0.77-1.37) | 0.841 | 1.03 (0.78-1.37) | 0.834 | |
| GG | 32 (11.64) | 67 (6.59) | 1.89 (1.19-2.99) | 0.007 | 1.89 (1.20-3.00) | 0.007 | |
| Additive | 0.045 | 1.23 (1.00-1.51) | 0.045 | 1.24 (1.01-1.52) | 0.044 | ||
| Dominant | 134 (48.73) | 459 (45.13) | 0.289 | 1.16 (0.89-1.51) | 0.289 | 1.16 (0.89-1.51) | 0.284 |
| Recessive | 243 (88.36) | 950 (93.41) | 0.005 | 1.87 (1.20-2.91) | 0.006 | 1.87 (1.20-2.92) | 0.006 |
| Combined effect of risk genotypes | |||||||
| 1 | 44 (16.00) | 219 (21.53) | 1.00 | 1.00 | |||
| 2 | 97 (35.27) | 350 (34.41) | 1.38 (0.93-2.05) | 0.100 | 1.37 (0.93-2.04) | 0.115 | |
| 3 | 92 (33.45) | 362 (35.59) | 1.27 (0.85-1.88) | 0.245 | 1.26 (0.85-1.88) | 0.249 | |
| 4 | 42 (15.27) | 86 (8.46) | 2.43 (1.49-3.97) | 0.0004 | 2.43 (1.48-3.96) | 0.0004 | |
| 1-3 | 233 (84.73) | 931 (91.54) | 1.00 | 1.00 | |||
| 4 | 42 (15.27) | 86 (8.46) | 0.0008 | 1.95 (1.31-2.90) | 0.0009 | 1.95 (1.31-2.90) | 0.0009 |
OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium. a χ2 test for genotype distributions between hepatoblastoma patients and controls, b Adjusted for age and gender, c Risk genotypes were carriers with rs314276 AA, rs221634 AA/AT, rs221635 TC/TT, rs9404590 TG/GG.